AMARIN CORP PLC\UK Recorded Unconditional Purchase Obligation, to be Paid, after Year Five
AMARIN CORP PLC\UK (AMRN) had Recorded Unconditional Purchase Obligation, to be Paid, after Year Five of $85.60 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Commitment and Contingencies › Recorded Unconditional Purchase Obligation, Fiscal Year Maturity Schedule
us-gaap:RecordedUnconditionalPurchaseObligationDueAfterFifthYear · last filed 2026-03-02
- 2025-12-31: Recorded Unconditional Purchase Obligation, to be Paid, after Year Five $85.60M.
- 2024-12-31: Recorded Unconditional Purchase Obligation, to be Paid, after Year Five $10.80M.
| Period end | Recorded Unconditional Purchase Obligation, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $85.60M 10-K · filed 2026-03-02 |
| 2024-12-31 | $10.80M 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |